SUBSCRIBE
SUBSCRIBE
News   Drug Development

Pfizer Inc. Drug Gets Thumbs-Down From U.K. Advisory Committee

April 18, 2006 | 
1 min read
LONDON (MarketWatch) -- A U.K. advisory committee on Tuesday said a new Pfizer Inc. inhaled insulin drug shouldn't be purchased by Britain's health service as the company's data doesn't show it's any better than existing alternatives.

Clinical research Postmarket research Regulatory Europe
Pfizer
MORE ON THIS TOPIC
FDA signage at its headquarters in Maryland
FDA
FDA’s Commissioner’s Priority Voucher Program ‘Shrouded in Secrecy,’ Democratic Rep Says
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
A close-up of a zebra standing in the Okavango Delta, showcasing its distinctive black and white stripes. The background is a blur of natural vegetation.
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
February 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Mechanical weight scale, body mass control concept : Bathroom scale on pale blue wood background. Analog scale operated with spring that pressure is calibrated to translate tension into a mass readout.
Obesity
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’
February 3, 2026
 · 
2 min read
 · 
Tristan Manalac